Washington University in St. Louis
St. Louis, Missouri
Brian Van Tine, M.D., Ph.D. is a Professor of Medicine and Pediatrics at Washington University in St Louis. He is the Sarcoma Program Director, Co-Director of the Phase 1 Program, and Co-Director of the AYA Program at the Alvin J. Siteman Cancer Center. Dr. Van Tine received his Bachelors of Science from the Departments of Chemistry and Biochemistry at The University of Arizona (1995). Dr. Van Tine completed his M.D. and Ph.D. degrees at the University of Alabama at Birmingham (2005). Dr. Van Tine then came to Washington University in St. Louis/Barnes Jewish Hospital where he did his Internal Medicine Residency and Medical Oncology Fellowship. He joined the labs of James J.D. Hsieh, and then Matthew Ellis, where he pursued his postdoctoral fellowship studying mouse genetics and genomics while clinically specializing in the treatment of sarcoma. His translational laboratory identified a common defect in sarcoma, the loss of ASS1 expression. His lab is working toward translating this finding to the clinic via clinical trials. They were first to report that argininosuccinate synthetase 1 is silenced in ~90% of sarcomas, which renders them susceptible to arginine deprivation therapy and glutaminase inhibitors because they cannot synthesize arginine. He has demonstrated that arginine starvation overcomes gemcitabine resistance in sarcoma, a concept being formally tested in a phase II prospective clinical trial. The laboratory was the first to identify the loss of malic enzyme 1 (ME1) in synovial sarcoma, a finding that has direct therapeutic consequences, as well as PHGDH dependency in osteosarcoma.
Adaptimmune (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Other Financial or Material Support, Travel to attend Ad Scientific Ad Board; ADRx (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Apexigen Inc (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Ayala Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Bayer (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Cytokinetics Inc (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Daiichi Sankyo (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Deciphera Pharmaceuticals, Inc (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Epizyme (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant, Other Financial or Material Support, Travel to attend Ad Scientific Ad Board; GSK (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Grant/Research Support, Other Financial or Material Support, Speaker's Bureau, Travel Support to present research; Lilly (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support; Novartis (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Pfizer (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support; Polaris (Individual(s) Involved: Self; Clinical Condition: Oncology): Board Member, Other Financial or Material Support; Tracon Pharm (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support
Friday, March 18, 2022
3:00 PM – 5:00 PM
Friday, March 18, 2022
3:25 PM – 3:30 PM
Friday, March 18, 2022
3:55 PM – 4:25 PM
Friday, September 16, 2022
11:50 AM – 1:40 PM
Friday, September 16, 2022
11:55 AM – 12:02 PM
Friday, September 16, 2022
12:10 PM – 12:15 PM
Friday, September 16, 2022
12:35 PM – 1:05 PM
Friday, September 16, 2022
1:05 PM – 1:35 PM